Transaction in Own Shares

PureTech Health PLC

27 November 2023

 

27 November 2023

PureTech Health plc

Transaction in Own Shares

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

Date of purchase:	24 November 2023
Number of ordinary shares purchased:	32,582
Highest price paid per share:	165.20p
Lowest price paid per share:	162.20p
Volume weighted average price paid per share:	163.39p

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 16,588,788 ordinary shares in treasury and has 272,879,371 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 272,879,371 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

For more information, visit www.puretechhealth.com or connect with us on X, formerly known as Twitter, @puretechh.

Contact:

PureTech

Investor Relations

[e-mail]

Individual Transactions

Transaction Date	Transaction Time	Volume	Price (GBp)	Platform	Transaction Reference Number
24/11/2023	08:15:26	507	165.2	XLON	00379762139TRLO0.1.1
24/11/2023	09:17:37	118	163.8	TRQX	00379770575TRLO0.1.1
24/11/2023	09:17:37	1014	164.2	CHIX	00379770574TRLO0.1.1
24/11/2023	09:17:37	507	164.2	XLON	00379770577TRLO0.1.1
24/11/2023	09:17:37	507	164.2	XLON	00379770576TRLO0.1.1
24/11/2023	10:40:42	240	164.2	CHIX	00379781661TRLO0.1.1
24/11/2023	10:40:59	363	164.2	XLON	00379781675TRLO0.1.1
24/11/2023	12:12:22	620	163	XLON	00379791766TRLO0.1.1
24/11/2023	12:12:22	49	163	XLON	00379791768TRLO0.1.1
24/11/2023	12:12:22	49	163	XLON	00379791767TRLO0.1.1
24/11/2023	12:20:28	3989	163	XLON	00379792505TRLO0.1.1
24/11/2023	12:20:28	507	162.8	XLON	00379792506TRLO0.1.1
24/11/2023	12:20:28	774	164	CHIX	00379792508TRLO0.1.1
24/11/2023	12:20:30	248	162.4	BATE	00379792521TRLO0.1.1
24/11/2023	12:20:30	259	162.4	BATE	00379792520TRLO0.1.1
24/11/2023	12:20:30	507	162.4	BATE	00379792522TRLO0.1.1
24/11/2023	12:20:30	507	162.4	CHIX	00379792523TRLO0.1.1
24/11/2023	12:20:30	63	162.4	CHIX	00379792524TRLO0.1.1
24/11/2023	12:20:30	273	162.4	CHIX	00379792525TRLO0.1.1
24/11/2023	12:20:35	118	162.2	TRQX	00379792534TRLO0.1.1
24/11/2023	12:20:35	69	162.2	TRQX	00379792535TRLO0.1.1
24/11/2023	12:20:35	49	162.2	TRQX	00379792536TRLO0.1.1
24/11/2023	13:16:39	12	163.8	XLON	00379797005TRLO0.1.1
24/11/2023	13:16:40	214	163.8	XLON	00379797006TRLO0.1.1
24/11/2023	13:16:40	7	163.8	XLON	00379797007TRLO0.1.1
24/11/2023	13:16:40	340	163.8	XLON	00379797008TRLO0.1.1
24/11/2023	13:16:40	264	163.8	XLON	00379797009TRLO0.1.1
24/11/2023	13:16:40	177	163.8	XLON	00379797010TRLO0.1.1
24/11/2023	13:18:45	350	164	XLON	00379797229TRLO0.1.1
24/11/2023	13:18:45	3150	164.2	XLON	00379797230TRLO0.1.1
24/11/2023	14:05:53	1202	163.2	XLON	00379801746TRLO0.1.1
24/11/2023	14:07:28	910	163	XLON	00379801878TRLO0.1.1
24/11/2023	14:42:06	635	163.2	XLON	00379814440TRLO0.1.1
24/11/2023	14:42:06	886	163.2	XLON	00379814439TRLO0.1.1
24/11/2023	14:42:07	457	163	CHIX	00379814446TRLO0.1.1
24/11/2023	14:42:07	50	163	CHIX	00379814445TRLO0.1.1
24/11/2023	14:42:07	369	163	CHIX	00379814447TRLO0.1.1
24/11/2023	14:42:07	177	163	AQXE	00379814448TRLO0.1.1
24/11/2023	14:42:07	138	163	CHIX	00379814449TRLO0.1.1
24/11/2023	14:50:11	507	162.6	BATE	00379818122TRLO0.1.1
24/11/2023	14:50:11	507	162.6	BATE	00379818123TRLO0.1.1
24/11/2023	15:16:17	1014	162.6	XLON	00379827444TRLO0.1.1
24/11/2023	15:41:32	119	163.4	XLON	00379835751TRLO0.1.1
24/11/2023	15:41:33	60	163.4	XLON	00379835752TRLO0.1.1
24/11/2023	15:41:33	1	163.4	XLON	00379835753TRLO0.1.1
24/11/2023	15:51:48	507	163.4	BATE	00379838757TRLO0.1.1
24/11/2023	15:51:48	234	163.4	CHIX	00379838758TRLO0.1.1
24/11/2023	15:51:48	1521	163.6	XLON	00379838759TRLO0.1.1
24/11/2023	15:51:48	273	163.4	CHIX	00379838760TRLO0.1.1
24/11/2023	15:51:48	118	163	TRQX	00379838761TRLO0.1.1
24/11/2023	15:51:52	350	164	AQXE	00379838775TRLO0.1.1
24/11/2023	15:51:52	531	164	AQXE	00379838776TRLO0.1.1
24/11/2023	16:10:31	639	163	XLON	00379844964TRLO0.1.1
24/11/2023	16:18:46	882	163	XLON	00379847596TRLO0.1.1
24/11/2023	16:29:34	1747	163.4	CHIX	00379851063TRLO0.1.1
24/11/2023	16:29:35	13	163.4	CHIX	00379851070TRLO0.1.1
24/11/2023	16:29:35	42	163.4	CHIX	00379851077TRLO0.1.1
24/11/2023	16:29:41	1693	163.4	CHIX	00379851146TRLO0.1.1
24/11/2023	16:29:42	225	163.4	CHIX	00379851167TRLO0.1.1
24/11/2023	16:29:43	246	162.8	XLON	00379851187TRLO0.1.1
24/11/2023	16:29:51	678	164	AQXE	00379851256TRLO0.1.1

 

END